Axsome Therapeutics (AXSM) Short Interest Ratio & Short Volume → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free AXSM Stock Alerts $76.60 +0.96 (+1.27%) (As of 02:22 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Axsome Therapeutics Short Interest DataCurrent Short Volume7,710,000 sharesPrevious Short Volume7,750,000 sharesChange Vs. Previous Month-0.52%Dollar Volume Sold Short$568.69 millionShort Interest Ratio / Days to Cover10.5Last Record DateApril 30, 2024Outstanding Shares47,496,000 sharesPercentage of Shares Shorted16.23%Today's Trading Volume231,559 sharesAverage Trading Volume703,928 sharesToday's Volume Vs. Average33% Short Selling Axsome Therapeutics ? Sign up to receive the latest short interest report for Axsome Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAXSM Short Interest Over TimeAXSM Days to Cover Over TimeAXSM Percentage of Float Shorted Over Time Ad Small Cap SniperRevolutionizing the Green Energy Space and Building Shareholder Value Along the WayAs the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely!Learn how this American company is leading the lithium-ion revolution Axsome Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20247,710,000 shares $568.69 million -0.5%N/A10.5 $73.76 4/15/20247,750,000 shares $528.63 million +1.3%N/A10.7 $68.21 3/31/20247,650,000 shares $610.47 million +4.8%N/A10.4 $79.80 3/15/20247,300,000 shares $551.44 million -2.3%N/A9.4 $75.54 2/29/20247,470,000 shares $607.91 million -0.7%N/A10.2 $81.38 2/15/20247,520,000 shares $702.82 million +0.4%N/A10.9 $93.46 Get the Latest News and Ratings for AXSM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20247,490,000 shares $674.32 million -10.0%N/A11.5 $90.03 1/15/20248,320,000 shares $708.95 million -1.2%N/A11.9 $85.21 12/31/20238,420,000 shares $670.15 million +0.7%N/A12.4 $79.59 12/15/20238,360,000 shares $610.20 million -1.1%N/A12.6 $72.99 11/30/20238,450,000 shares $569.95 million +10.6%N/A12.3 $67.45 11/15/20237,640,000 shares $460.00 million +4.0%N/A11.5 $60.21 10/31/20237,350,000 shares $457.76 million -3.2%N/A11 $62.28 10/15/20237,590,000 shares $504.51 million +1.6%N/A10.9 $66.47 9/30/20237,470,000 shares $522.08 million -8.0%N/A10.4 $69.89 9/15/20238,120,000 shares $611.11 million -1.5%N/A9.6 $75.26 8/31/20238,240,000 shares $665.79 million -3.5%N/A9.3 $80.80 8/15/20238,540,000 shares $609.41 million -5.7%N/A9.4 $71.36 7/31/20239,060,000 shares $710.94 million -2.6%N/A9.6 $78.47 7/15/20239,300,000 shares $684.76 million +1.8%N/A10.5 $73.63 6/30/20239,140,000 shares $656.80 million +17.8%24.5%10.1 $71.86 6/15/20237,760,000 shares $656.73 million +0.3%22.2%9.9 $84.63 5/31/20237,740,000 shares $571.06 million +0.9%22.2%9.9 $73.78 5/15/20237,670,000 shares $596.50 million -4.0%22.0%9.1 $77.77 4/30/20237,990,000 shares $571.52 million +1.9%23.3%8.9 $71.53 4/15/20237,840,000 shares $537.04 million -4.5%22.8%8.6 $68.50 3/31/20238,210,000 shares $506.39 million -3.8%23.9%8.7 $61.68 3/15/20238,530,000 shares $528.26 million +1.6%24.8%8.9 $61.93 2/28/20238,400,000 shares $572.80 million +4.4%24.5%8.5 $68.19 2/15/20238,050,000 shares $508.28 million +5.4%23.5%6.9 $63.14 1/31/20237,640,000 shares $573 million -3.8%21.6%6.2 $75.00 1/15/20237,940,000 shares $534.36 million +5.2%22.4%5.9 $67.30 12/30/20227,550,000 shares $582.33 million +2.4%21.3%5.4 $77.13 12/15/20227,370,000 shares $570.88 million -7.1%20.8%5.1 $77.46 11/30/20227,930,000 shares $573.26 million +16.8%22.8%5.3 $72.29 11/15/20226,790,000 shares $372.91 million +9.0%19.5%5.2 $54.92 10/31/20226,230,000 shares $281.28 million +8.5%19.3%3.6 $45.15 10/15/20225,740,000 shares $275.52 million +2.5%17.8%3.7 $48.00 9/30/20225,600,000 shares $249.87 million -1.8%17.4%3.8 $44.62 9/15/20225,700,000 shares $351.63 million -3.7%17.7%2.9 $61.69Look Who Fired the World’s Richest Man (Ad)This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman.Get the full story here. AXSM Short Interest - Frequently Asked Questions What is Axsome Therapeutics' current short interest? Short interest is the volume of Axsome Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 7,710,000 shares of AXSM short. Learn More on Axsome Therapeutics' current short interest. What is a good short interest ratio for Axsome Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AXSM shares currently have a short interest ratio of 10.0. Learn More on Axsome Therapeutics's short interest ratio. Which institutional investors are shorting Axsome Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Axsome Therapeutics: Concourse Financial Group Securities Inc., SpiderRock Advisors LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Axsome Therapeutics' short interest increasing or decreasing? Axsome Therapeutics saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 7,710,000 shares, a drop of 0.5% from the previous total of 7,750,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Axsome Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Axsome Therapeutics: Biohaven Ltd. (10.91%), Summit Therapeutics Inc. (28.19%), Crinetics Pharmaceuticals, Inc. (6.23%), Ultragenyx Pharmaceutical Inc. (5.59%), Prestige Consumer Healthcare Inc. (3.79%), Insmed Incorporated (5.74%), HUTCHMED (China) Limited (0.26%), Xenon Pharmaceuticals Inc. (3.70%), Alkermes plc (7.62%), Perrigo Company plc (2.54%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Axsome Therapeutics stock? Short selling AXSM is an investing strategy that aims to generate trading profit from Axsome Therapeutics as its price is falling. AXSM shares are trading up $0.96 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Axsome Therapeutics? A short squeeze for Axsome Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of AXSM, which in turn drives the price of the stock up even further. How often is Axsome Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AXSM, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Biohaven Short Interest Summit Therapeutics Short Interest Crinetics Pharmaceuticals Short Interest Ultragenyx Pharmaceutical Short Interest Prestige Consumer Healthcare Short Interest Insmed Short Interest HUTCHMED Short Interest Xenon Pharmaceuticals Short Interest Alkermes Short Interest Perrigo Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AXSM) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlace